<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04271917</url>
  </required_header>
  <id_info>
    <org_study_id>20-07123-XP</org_study_id>
    <nct_id>NCT04271917</nct_id>
  </id_info>
  <brief_title>Analgesic Effects of Cannabidiol for Simple Tooth Extractions in Dental Patients</brief_title>
  <acronym>SWAP</acronym>
  <official_title>Surgery With Alternative Pain Management (SWAP): Analgesic Effects of Cannabidiol for Simple Tooth Extractions in Dental Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Tennessee</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Tennessee</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the analgesic effects of cannabidiol for patients
      who have undergone simple tooth extraction. Participants will be randomized to one of four
      arms: treatment-as-usual (TAU), cannabidiol 17mg/mL, cannabidiol 37mg/mL, or placebo.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 17, 2020</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>Since TAU participants will receive tablets instead of oil like the other 3 arms, the design is not completely double-blinded; however, the study will be double-blinded between the other three arms which all receive oil in a dropper vial.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Worst pain following surgery using Wong Baker Faces pain scale</measure>
    <time_frame>1-week post-op</time_frame>
    <description>Self-report of participant's worst pain after surgery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount of medication used</measure>
    <time_frame>1-week post-op</time_frame>
    <description>Self-report of total amount of pain medication used from participant diary</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain levels following surgery using Wong Baker Faces pain scale</measure>
    <time_frame>First 72 hours post-op</time_frame>
    <description>Self-reported pain recorded every 2 hours between 7am-9pm by automated SMS messaging.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Pain, Acute</condition>
  <arm_group>
    <arm_group_label>Treatment As Usual (TAU)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive a 5-day supply of acetaminophen 500mg and ibuprofen 200mg.
Instructions for use: Take one tablet of each medication at the same time every 4-6 hours as needed for pain.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive a 5-day supply (15mL) of inactive placebo in a dropper vial.
Instructions for use: Place 0.5mL of oil under tongue for 30 seconds then swallow. Use every 4-6 hours as needed for pain.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CBD 17mg/mL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a 5-day supply (15mL) of cannabidiol 17mg/mL.
Instructions for use: Place 0.5mL of oil under tongue for 30 seconds then swallow. Use every 4-6 hours as needed for pain.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CBD 37 mg/mL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a 5-day supply (15mL) of cannabidiol 37mg/mL.
Instructions for use: Place 0.5mL of oil under tongue for 30 seconds then swallow. Use every 4-6 hours as needed for pain.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cannabidiol</intervention_name>
    <description>Use of cannabidiol as an alternative to standard of care treatment of acute pain.</description>
    <arm_group_label>CBD 17mg/mL</arm_group_label>
    <arm_group_label>CBD 37 mg/mL</arm_group_label>
    <other_name>CBD oil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Inactive placebo oil to imitate CBD oil</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>acetaminophen 500mg and ibuprofen 200mg combo</intervention_name>
    <description>standard of care</description>
    <arm_group_label>Treatment As Usual (TAU)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Presenting for an operatory appointment at University of Tennessee Health Science
             Center College of Dentistry Oral and Maxillofacial Surgery Department

          -  Operation must be a simple tooth extraction which does not result in an opioid
             prescription

          -  18 years of age or older

          -  Have regular and direct access to a device that can send and receive texts and willing
             to accept any associated charges for 24 text messages

        Exclusion Criteria:

          -  Contraindication to ibuprofen

          -  Contraindication to acetaminophen

          -  Contraindication to cannabidiol or hemp oil

          -  Contraindication to peppermint oil

          -  Contraindication to almond or other tree nuts

          -  Currently taking a form of cannabidiol and unwilling to stop use for one week post
             surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen J Derefinko, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Tennessee</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ammaar H Abidi, DDS, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Tennessee</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sarah Hand, MPH</last_name>
    <phone>901-448-3072</phone>
    <email>shand@uthsc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Tennessee Health Science Center</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38163</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Sarah Hand, MPH</last_name>
      <phone>901-448-3072</phone>
      <email>shand@uthsc.edu</email>
    </contact>
    <investigator>
      <last_name>Karen J Derefinko, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ammaar H Abidi, DDS,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 12, 2020</study_first_submitted>
  <study_first_submitted_qc>February 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2020</study_first_posted>
  <last_update_submitted>February 14, 2020</last_update_submitted>
  <last_update_submitted_qc>February 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Tennessee Health Science Center</investigator_affiliation>
    <investigator_full_name>Karen Derefinko</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>cannabidiol</keyword>
  <keyword>CBD</keyword>
  <keyword>acute pain</keyword>
  <keyword>alternative pain management</keyword>
  <keyword>simple extraction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Ibuprofen</mesh_term>
    <mesh_term>Epidiolex</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

